STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb’s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
conferences earnings clinical trial
IMPACT
SENTIMENT
BMY : NYSE
Milvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
clinical trial
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb’s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb Receives European Commission Approval for CAR T Cell Therapy Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb to Participate in Bank of America Securities 2023 Healthcare Conference
conferences
IMPACT
SENTIMENT
BMY : NYSE
U.S. FDA Accepts for Priority Review Supplemental Biologics License Application and EMA Validates Application for Reblozyl® (luspatercept-aamt) as First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
IMPACT
SENTIMENT
BMY : NYSE
Bristol Myers Squibb’s TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma Meet Primary Endpoint of Overall Response Rate
clinical trial
Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#117 Ranked by Market Cap
#4058 Ranked by Stock Gains
#651 Ranked by Dividends

BMY Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
New York

About BMY

The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.